INTRODUCTION {#s1}
============

Esophagogastric junction adenocarcinoma (EGJA) is a common malignancy in North America, Europe and Eastern Asian and is considered that it is different from distal GC \[[@R1]--[@R3]\]. In the United States, the data of cancer registry program showed the incidence of EGJA increased 2.5-fold from 1973--1992, and it was stable in the last two decades with 2 per 100,000 morbidity \[[@R4]\]. In Caucasians, the 5-year relative survival rate was 16--17% \[[@R4], [@R5]\]. It is also reported that EGJA is a serious public health problem with high mortality in China. Liu *et al.* reported that the incidence of EGJA was 34.1% in all gastric and esophageal adenocarcinomas patients \[[@R6]\]. And 5-year survival rate of EGJA was 29--35.5% \[[@R7], [@R8]\]. The pathological process of EGJA is very complex. The etiology of EGJA is unclear. It is believed that food preserved by salting, chronic gastroesophageal reflux disease, smoking, obesity and etc. may contribute to the development of EGJA. Nowadays, accumulating evidences highlighted that individual\'s genetic background could play a vital role in the carcinogenesis of EGJA. Single nucleotide polymorphisms (SNPs), which could alter the activity of some detoxifying carcinogenic substances, may conduce to the development of EGJA.

Chronic inflammation may influence the susceptibility of malignancy. The potential molecular mechanisms underlying the relationship have been studied and it is identified that a number of inflammation-related cells gathers and secretes some chemical mediators, in particular reactive oxygen species (ROS) \[[@R9]\]. ROS levels within cells and inflammatory tissues are regulated by many free-radical scavenging systems. The excessive ROS damage intracellular macromolecules, including proteins and nucleic acids. *Paraoxonase 1* (*PON1*) gene maps to the long arm of chromosome 7. PON1, an antioxidant enzyme, keeps the balance of antioxidant--oxidant \[[@R10]--[@R13]\]. Enzyme Commission of the International Union of Biochemistry and Molecular Biology classifies PON1 as an aryldialkylphosphatase (EC 3.1.8.1) \[[@R14]\]. PON1, a glycoprotein, is a molecular mass of 43KDa. Oxidative stress have been found to be correlated with an increased susceptibility of many malignancies \[[@R9]\]. *In vivo*, body possesses several free-radical scavenging systems including paraoxonase. PON1 prevents the oxidation of LDL and cell membrane, and therefore it is thought to be atheroprotective. Furthermore, PON1 was found to play an important role in the scavenging of carcinogenic lipid-soluble radicals \[[@R15]\]. In addition, PON1 is versatile and it may contribute to innate immunity, putative new roles in malignancy and the promotion of healthy aging \[[@R16]\]. It was reported that expression or activity of PON1 decreased in lung cancer, multiple myeloma and papillary thyroid cancer \[[@R17]--[@R19]\]. Therefore, it is reasonable to believe that the decreased activity of PON1 may be associate with the development of cancer.

*PON1* rs662 C\>T and rs854560 A\>T, two functional SNPs, were identified to be associated with the risk of multiple cancers \[[@R20]--[@R22]\]. However, most of the epidemiologic and molecular studies focused on the relationship of *PON1* polymorphisms with the risk of cancer in Caucasians. Thus, the results might remain inconclusive, especially in Asians. Therefore, we conducted this case-control study to determine the association between *PON1* rs662 C\>T, rs854560 A\>T polymorphisms and EGJA risk with a large sample size in Eastern Chinese Han populations.

RESULTS {#s2}
=======

Baseline characteristics {#s2_1}
------------------------

The relevant demographics and risk factors are summarized by case/control status in Table [1](#T1){ref-type="table"}. EGJA patients and non-cancer controls were similar in terms of age and sex distributions. There were more smokers and drinkers among EGJA patients than among controls. The minor allele frequency (MAF) of *PON-1* rs854560 A\>T and rs662 C\>T polymorphisms in controls was similar to its data in the database (Table [2](#T2){ref-type="table"}). In controls, as demonstrated in Table [2](#T2){ref-type="table"}, the *PON-1* rs854560 A\>T and rs662 C\>T genotypes distribution accorded with Hardy--Weinberg equilibrium (HWE).

###### Distribution of selected demographic variables and risk factors

  Variable         Overall Cases (*n* = 1,063)   Overall Controls (*n* = 1,677)   *P*^a^           
  ---------------- ----------------------------- -------------------------------- -------- ------- ----------
  Age (years)      64.19 (± 8.63)                63.91 (± 10.22)                  0.451            
  Age (years)                                                                                      0.165
   \< 64           494                           46.47                            825      49.19   
   ≥ 64            569                           53.53                            852      50.81   
  Sex                                                                                              0.909
   Female          304                           28.60                            483      28.80   
   Male            759                           71.40                            1194     71.20   
  Smoking status                                                                                   \< 0.001
   Never           773                           72.72                            1323     78.89   
   Ever            290                           27.28                            354      21.11   
  Alcohol use                                                                                      \< 0.001
   Never           908                           85.42                            1507     89.86   
   Ever            155                           14.58                            170      10.14   

^a^ Two-sided *χ*^2^ test and Student t test.

###### Primary information for *PON1* polymorphisms (rs854560 A\>T and rs662 C\>T)

  Genotyped polymorphisms                                rs854560 A\>T      rs662 C\>T
  ------------------------------------------------------ ------------------ ------------------
  Chr                                                    7                  7
  NCBI Build 38^a^                                       95316772           95308134
  Function^a^                                            missense (dbSNP)   missense (dbSNP)
  Minor allele frequency a for Chinese in database ^a^   0.03               0.43
  Minor allele frequency in our controls (*n* = 1,677)   0.03               0.36
  *P* value for HWE^b^ test in our controls              0.733              0.632
  \% Genotyping value                                    99.09              99.09

^a^ <http://gvs.gs.washington.edu/GVS147/>

^b^HWE: Hardy--Weinberg equilibrium.

Association of *PON-1* rs662 C\>T and rs854560 A\>T polymorphisms with EGJA {#s2_2}
---------------------------------------------------------------------------

The *PON-1* rs854560 A\>T and rs662 C\>T genotypes are summarized in Table [3](#T3){ref-type="table"}. The frequencies of *PON-1* rs854560 AA, AT, and TT genotypes were 93.28%, 6.63% and 0.10% in EGJA group and 93.97%, 5.91%, and 0.12% in controls, respectively. When the frequency of *PON-1* rs854560 AA genotype was used as reference, there was no difference in the frequency of *PON-1* rs854560 AT genotype between the EGJA group and the controls (crude OR = 1.11, 95% CI: 0.81--1.52, *P* = 0.533). When the frequency of *PON-1* rs854560 AA genotype was used as reference, we found no difference in the frequency of *PON-1* rs854560 TT genotype between EGJA group and the controls (crude OR = 0.79, 95% CI: 0.07--8.76, *P* = 0.850). In addition, when the frequency of *PON-1* rs854560 AA genotype was used as reference, there was no difference in the frequency of *PON-1* rs854560 AT/TT genotypes between EGJA group and the controls (crude OR = 1.12, 95% CI: 0.82--1.54, *P* = 0.471). When the frequency of *PON-1* rs854560 AA/AT genotypes were used as reference, we found there was no difference in the frequency of *PON-1* rs854560 TT genotype between EGJA group and the controls (crude OR = 0.80, 95% CI: 0.07--8.88, *P* = 0.859). Adjustment for age, sex, smoking and drinking, the similar results were also found (AT vs. AA: adjusted OR, 1.12; 95% CI, 0.81--1.54; *P* = 0.488; TT vs. AA: adjusted OR, 0.90; 95% CI, 0.08--9.98; *P* = 0.933; TT/AT vs. AA: adjusted OR, 1.14; 95% CI, 0.83--1.56; *P* = 0.417; TT vs. AA/AT: adjusted OR, 0.92; 95% CI, 0.08--10.16; *P* = 0.945; Table [4](#T4){ref-type="table"}).

###### The frequencies of *PON1* rs854560 A\>T and rs662 C\>T polymorphisms

  Genotype        Overall EGJA case (*n* = 1,063)   Overall Controls (*n* = 1,677)           
  --------------- --------------------------------- -------------------------------- ------- -------
  rs854560 A\>T                                                                              
  AA              971                               93.28                            1573    93.97
  AT              69                                6.63                             99      5.91
  TT              1                                 0.10                             2       0.12
  AT + TT         70                                6.72                             101     6.03
  AA + AT         1040                              99.90                            1,672   99.88
  T allele        71                                3.41                             103     3.08
  rs662 C\>T                                                                                 
  CC              408                               39.19                            691     41.28
  CT              501                               48.13                            776     46.36
  TT              132                               12.68                            207     12.37
  TT + CT         633                               60.81                            983     58.72
  CT + CC         909                               87.32                            1,467   87.63
  T allele        765                               36.70                            1,190   35.54

EGJA patients and controls.

###### Analyses of the association between *PON1* rs854560 A\>T, rs662 C\>T polymorphisms and the risk of EGJA

  Genotype           Overall (1,063 cases vs. 1,677 controls)                                
  ------------------ ------------------------------------------ ------- -------------------- -------
  rs854560 A\>T                                                                              
  additive model     1.11 (0.81--1.52)                          0.533   1.12 (0.81--1.54)    0.488
  homozygote model   0.79 (0.07--8.76)                          0.850   0.90 (0.08--9.98)    0.933
  Dominant model     1.12 (0.82--1.54)                          0.471   1.14 (0.83--1.56)    0.417
  Recessive model    0.80 (0.07--8.88)                          0.859   0.92 (0.08--10.16)   0.945
  rs662 C\>T                                                                                 
  additive model     1.04 (0.88--1.23)                          0.624   1.04 (0.88--1.23)    0.651
  homozygote model   1.03 (0.80--1.32)                          0.821   1.01 (0.79--1.30)    0.929
  Dominant model     1.09 (0.93--1.28)                          0.282   1.09 (0.93--1.27)    0.315
  Recessive model    1.03 (0.82--1.30)                          0.809   1.01 (0.80--1.28)    0.915

^a^Adjusted for age, sex, smoking status and alcohol use in a logistic regression model.

The frequencies of *PON-1* rs662 CC, CT, and TT genotypes were 39.19%, 48.13% and 12.68% in EGJA group and 41.28%, 46.36%, and 12.37% in controls, respectively. When the frequency of rs662 CC genotype was used as reference, there was no difference in the frequency of *PON-1* rs662 CT genotype between the EGJA group and the controls (crude OR = 1.04, 95% CI: 0.88--1.23, *P* = 0.624). When the frequency of *PON-1* rs662 CC genotype was used as reference, we found there was no difference in the frequency of *PON-1* rs662 TT genotype between EGJA group and the controls (crude OR = 1.03, 95% CI: 0.80--1.32, *P* = 0.821). In addition, when the frequency of *PON-1* rs662 CC genotype was used as reference, there was no difference in the frequency of *PON-1* rs662 CT/TT genotypes between EGJA group and the controls (crude OR = 1.09, 95% CI: 0.93--1.28, *P* = 0.282). When the frequency of *PON-1* rs662 CC/CT genotypes were used as reference, no difference was found in the frequency of *PON-1* rs662 TT genotype between EGJA group and the controls (crude OR = 1.03, 95% CI: 0.82--1.30, *P* = 0.809). Adjustment for age, sex, smoking and drinking, the similar results were also found (CT vs. CC: adjusted OR, 1.04; 95% CI, 0.88--1.23; *P* = 0.651; TT vs. CC: adjusted OR, 1.01; 95% CI, 0.79--1.30; *P* = 0.929; TT/CT vs. CC: adjusted OR, 1.09; 95% CI, 0.93--1.27; *P* = 0.315; TT vs. CC/CT: adjusted OR, 1.01; 95% CI, 0.80--1.28; *P* = 0.915; Table [4](#T4){ref-type="table"}).

Association of *PON-1* rs662 C\>T and rs854560 A\>T polymorphisms with EGJA in Different Stratification Groups {#s2_3}
--------------------------------------------------------------------------------------------------------------

The *PON-1* rs854560 A\>T genotype frequencies in the different stratified analyses are summarized in Table [5](#T5){ref-type="table"}. We found that *PON-1* rs854560 A\>T polymorphism was not associated with the risk of EGJA in any subgroup (Table [5](#T5){ref-type="table"}).

###### Stratified analyses between *PON-1* rs854560 A\>T polymorphism and EGJA risk by sex, age, smoking status and alcohol consumption

  Variable              *PON-1* rs854560 A\>T (case/control) a   Adjusted OR b (95% CI); P                                                                                                                 
  --------------------- ---------------------------------------- --------------------------- ----- ------ ------------------------------- -------------------------------- ------------------------------- --------------------------------
  Sex                                                                                                                                                                                                      
  Male                  696/1222                                 49/68                       1/1   1.00   1.17 (0.80--1.71); *P*: 0.422   1.84 (0.12--29.48); *P*: 0.667   1.20 (0.82--1.75); *P*: 0.347   1.86 (0.12--29.79); *P*: 0.661
  Female                275/451                                  20/31                       0/1   1.00   0.95 (0.53--1.72); *P*: 0.875   \-                               0.96 (0.53--1.72); *P*: 0.885   \-
  Age                                                                                                                                                                                                      
  \< 64                 449/777                                  32/45                       1/1   1.00   1.19 (0.74--1.90); *P*: 0.479   2.00 (0.12--32.03); *P*: 0.625   1.23 (0.77--1.96); *P*: 0.383   2.03 (0.13--32.61); *P*: 0.617
  ≥ 64                  522/796                                  37/54                       0/1   1.00   1.03 (0.66--1.59); *P*: 0.908   \-                               1.03 (0.67--1.59); *P*: 0.894   \-
  Smoking status                                                                                                                                                                                           
  Never                 700/1,239                                53/80                       1/2   1.00   1.13 (0.79--1.62); *P*: 0.501   0.89 (0.08--9.84); *P*: 0.923    1.16 (0.81--1.65); *P*: 0.429   0.90 (0.08--10.00); *P*: 0.934
  Ever                  271/334                                  16/19                       0/0   1.00   1.04 (0.52--2.08); *P*: 0.919   \-                               1.05 (0.52--2.10); *P*: 0.900   \-
  Alcohol consumption                                                                                                                                                                                      
  Never                 823/1414                                 63/89                       1/2   1.00   1.18 (0.84--1.64); *P*: 0.342   0.89 (0.08--9.83); *P*: 0.923    1.20 (0.86--1.67); *P*: 0.285   0.90 (0.08--9.98); *P*: 0.932
  Ever                  148/159                                  6/10                        0/0   1.00   0.58 (0.20--1.70); *P*: 0.320   \-                               0.58 (0.20--1.71); *P*: 0.325   \-

^a^ The genotyping was successful in 1063 (97.93%) EGJA cases, and 1677 (99.82%) controls for *PON-1* rs854560 A\>T.

^b^ Adjusted for age, sex, smoking status and alcohol consumption (besides stratified factors accordingly) in a logistic regression model.

The *PON-1* rs662 C\>T genotype frequencies in the different stratified analyses are summarized in Table [6](#T6){ref-type="table"}. After adjustment by logistic regression analysis, the results indicated that *PON-1* rs662 C\>T polymorphism might be associated with a significantly decreased risk of EGJA in ever smoking group \[TT vs. CC/CT: adjusted OR = 0.58, 95% CI 0.35--0.95, *P* = 0.029 (Table [6](#T6){ref-type="table"})\]. In other subgroups, we did not find any association between *PON-1* rs662 C\>T polymorphism and the risk of EGJA (Table [6](#T6){ref-type="table"}).

###### Stratified analyses between *PON-1* rs662 C\>T polymorphism and EGJA risk by sex, age, smoking status and alcohol consumption

  Variable              PON--1 rs662 C\>T (case/control)^a^   Adjusted OR b (95% CI); *P*                                                                                                                    
  --------------------- ------------------------------------- ----------------------------- --------- ------ ------------------------------- ------------------------------- ------------------------------- ---------------------------------
  Sex                                                                                                                                                                                                        
  Male                  285/488                               370/553                       91/150    1.00   1.10 (0.90--1.34); *P*: 0.344   0.98 (0.73--1.32); *P*: 0.902   1.12 (0.93--1.35); *P*: 0.250   0.95 (0.72--1.25); *P*: 0.706
  Female                123/203                               131/223                       41/57     1.00   0.90 (0.66--1.23); *P*: 0.504   1.08 (0.68--1.72); *P*: 0.740   1.01 (0.75--1.36); *P*: 0.962   1.18 (0.76--1.83); *P*: 0.452
  Age                                                                                                                                                                                                        
  \< 64                 197/340                               228/383                       57/100    1.00   0.96 (0.76--1.23); *P*: 0.765   0.90 (0.62--1.31); *P*: 0.592   1.01 (0.80--1.27); *P*: 0.969   0.94 (0.67--1.34); *P*: 0.749
  ≥ 64                  211/351                               273/393                       75/107    1.00   1.11 (0.89--1.40); *P*: 0.363   1.11 (0.79--1.56); *P*: 0.556   1.16 (0.93--1.45); *P*: 0.183   1.07 (0.78--1.47); *P*: 0.694
  Smoking status                                                                                                                                                                                             
  Never                 301/539                               350/628                       103/154   1.00   0.94 (0.78--1.14); *P*: 0.546   1.13 (0.85--1.50); *P*: 0.403   1.04 (0.86--1.25); *P*: 0.693   1.20 (0.92--1.57); *P*: 0.188
  Ever                  107/152                               151/148                       29/53     1.00   1.40 (0.99--1.96); *P*: 0.054   0.69 (0.41--1.16); *P*: 0.160   1.23 (0.89--1.70); *P*: 0.216   **0.58 (0.35--0.95); P: 0.029**
  Alcohol consumption                                                                                                                                                                                        
  Never                 354/627                               422/700                       111/178   1.00   1.01 (0.85--1.21); *P*: 0.897   1.04 (0.80--1.37); *P*: 0.760   1.08 (0.91--1.27); *P*: 0.398   1.06 (0.83--1.37); *P*: 0.634
  Ever                  54/64                                 79/76                         21/29     1.00   1.21 (0.74--1.99); *P*: 0.443   0.91 (0.45--1.81); *P*: 0.778   1.13 (0.70--1.81); *P*: 0.615   0.81 (0.43--1.53); *P*: 0.512

^a^ The genotyping was successful in 1063 (97.93%) EGJA cases, and 1677 (99.82%) controls for *PON-1* rs662 C\>T.

^b^ Adjusted for age, sex, smoking status and alcohol consumption (besides stratified factors accordingly) in a logistic regression model.

DISCUSSION {#s3}
==========

EGJA is thought to be an independent malignancy entirety of upper digestive tract tumors \[[@R23]\]. It is reported that the incidence of EGJA is increasing worldwide \[[@R1]--[@R3], [@R24]\]. A number of previous studies indicated that dietary habits, lifestyle (e.g. smoking and drinking *et al.*), oxidative and carbonyl stresses, and estrogens might play important roles in carcinogenesis \[[@R25]--[@R30]\]. *In vivo*, there are many antioxidant enzyme which may prevent genotoxic damage. PON1, an antioxidant enzyme, may play a vital role in keeping the balance of antioxidant--oxidant balance \[[@R11], [@R31]\]. Several studies reported that expression or activity of PON1 decreased in several cancers \[[@R17]--[@R19]\]. Considering the potential role of PON1 in carcinogenesis, we selected two most common *PON1* polymorphisms (rs662 C\>T and rs854560 A\>T) and assessed their susceptibility to EGJA. In this study, we identified that *PON1* rs662 C\>T polymorphism was associated with the decrease the risk of EGJA in ever smoking subgroup.

It was found that expression or activity of PON1 was lower in cancer patients than controls \[[@R17]--[@R19]\]. Delimaris *et al.* reported that oxidative stress might contribute to pathogenesis of cancer involving the proliferation and malignancy conversion \[[@R32]\]. Previous studies demonstrated that the variants of the *PON1* could affect the activity of PON1 protein. Thus, it was necessary to predict whether *PON1* polymorphisms might influence the development of EGJA. In this case-control study, we aimed to determine the relationship between *PON1* polymorphisms and EGJA risk. We found that *PON1* rs662 T allele might decrease the risk of EGJA in ever smoking subgroup, suggesting that *PON1* rs662 C\>T polymorphism might act as a protective factor for EGJA. Kahraman *et al.* found tobacco exposure increased oxidative stress and decreased paraoxonase-1 \[[@R33]\]. The coding region *PON1* rs662 C\>T polymorphism (R192Q) leads to an amino acid substitution and determines a substrate dependent effect on activity. Eom *et al.* reported that *PON1* rs662 TT/CT carriers had the lower urinary 8-hydroxydeoxyguanosine and thiobarbituric acid reactive substances levels compared with rs662 CC carriers in lung cancer patients and decreased the risk of lung cancer \[[@R34]\]. Recently, the association between the decreased risk of cancer and *PON1* rs662 C\>T polymorphism was also found in Asians \[[@R35]\]. Our findings were similar to the results of these studies. However, there were only a few case-control studies with small sample size conducted in Asians. The evidence might be limited. In the future, more case-control studies focusing on the relationship of *PON1* rs662 C\>T polymorphism with cancer risk should be performed to confirm these potential associations.

There are some limitations which may be interpreted. Firstly, although the number of the participants was relatively large, when the stratification analyses were carried out for the age, sex, smoking and drinking status, resulting in insufficient capacity which limited the power of this study. Secondly, the enrolled participants were from local hospitals, which might lead to the bias. Thirdly, there were only two missense SNPs in *PON1* gene included in this case-control study. In the future, a fine-mapping study should be performed to further determine the potential association between the functional SNPs in *PON1* gene and EGJA risk. Fourthly, only the information of drinking and smoking was collected as major risk factor. Other potential risk factors \[e.g. gastroesophageal reflux disease, obesity, Helicobacter pylori infection status and dietary behavior (low intake of fruit and veggies, pickled food consumption, and drinking beverages at high temperatures etc.)\] were not considered. Fifthly, biomarkers for oxidative stress were not measured in our study. Finally, for lack of raw data from other lifestyles, we did not further assess the relationships for the potential interactions of gene-gene or gene-environment factors.

In conclusion, our study highlights *PON1* rs662 C\>T polymorphism may be correlated with the decreased risk of EGJA which interacted with the tobacco using. In the future, a fine-mapping case-control study are needed to further assess the potential relationship between *PON1* SNPs and EGJA risk.

MATERIALS AND METHODS {#s4}
=====================

Subjects {#s4_1}
--------

This case-control study enrolled 2,740 participants of Asians origin from the Chinese Han population. Cases (*n* = 1,063) were newly diagnosed EGJA patients at Fujian Medical University Union Hospital and Fujian Medical University Cancer Hospital from January 2014 to May 2016, and at Affiliated People\'s Hospital of Jiangsu University from January 2008 to November 2016. EGJA patients were included consecutively. Two experienced pathologists confirmed the diagnosis of EGJA for all cases. The major selection criterion for EGJA cases were: (a) all EGJA cases were Siewert II subtype; (b) Patients were Eastern Chinese Han population, and (c) EGJA was confirmed via histopathological examinations. The major exclusion criteria for EGJA cases were: (1) had a history of personal autoimmune disease, (2) EGJA cases who received prior chemoradiotherapy and (3) had a history of another malignancy. At the same time, non-cancer controls were recruited from the Physical Examination Center of these local hospitals. The control subjects had no history of autoimmune disorder or personal malignancy, and were frequency matched to EGJA patients by sex and age. These subjects have been reported in our previous study \[[@R36]\].

Two trained personnels interviewed each participant. The demographic and lifestyle characteristics were obtained by using a questionnaire. Information on smoking, drinking, age and sex was collected for the present study. All participants were informed and signed written consent to allow their blood samples to be genetically tested. Approval was given by the ethical committees of Jiangsu University and Fujian Medical University, in accordance with the Declaration of Helsinki.

DNA extraction and genotyping {#s4_2}
-----------------------------

DNA from the participants was extracted from (EDTA)-anticoagulated blood samples with Promega DNA Kit (Promega, Madison, USA). The obtained DNA sample was stored at −80°C. Genotyping was carried out by using SNPscan^™^ assay (Genesky Biotechologies Inc., Shanghai, China) to determine the genotypes of *PON-1* rs854560 A\>T and rs662 C\>T polymorphisms. For quality control, 110 DNA samples randomly selected from 2,740 specimens were reanalyzed. The genotypes of *PON-1* rs854560 A\>T and rs662 C\>T polymorphisms were confirmed by another laboratory technicians. As shown in Table [2](#T2){ref-type="table"}, the success rate of *PON-1* genotyping was both more than 99%.

Statistical analysis {#s4_3}
--------------------

The HWE in controls was tested by the internet-based *χ*^2^ test (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>). The categorical variables (e.g. genotype distributions, age, sex, smoking status, and alcohol consumption) were compared by using Chi-square test (*χ*^2^). The continuous variable was compared by using Student\'s t-test. To test the hypothesis of relationship of *PON-1* genetic polymorphisms with EGJA risk, multivariate logistic regression analyses were used. The SAS 9.4 statistical package (SAS Institute Inc., Cary, NC, USA) was harnessed to calculate the results.
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